Gsk Share Discussion Threads

[tradermichael] 31/10/2023 13:04

6 ...

GSK has secured a $1 billion deal with Janssen, a Johnson & Johnson subsidiary, for the exclusive rights to further develop and commercialize the latter's hepatitis B therapy.

The therapy, known as JNJ-3989, was initially developed and licensed to Janssen by Arrowhead Pharmaceuticals (NASDAQ:ARWR) in 2018. The agreement will bolster GSK's own hepatitis B treatment, bepirovirsen.

With the acquisition of these exclusive rights, GSK aims to expand its portfolio in the treatment of hepatitis B, a disease affecting millions worldwide. The deal signifies a significant step in GSK's strategy to consolidate its position in the global pharmaceutical market.

[mj19] 30/10/2023 11:49

GSK doing all the right things. Only a matter of time before it rises and stays up and will keep going.....I am sure someone will bid for it now that it's a pure pharma

[tuftymatt] 28/10/2023 08:24

Yes I got back in too before the bell yesterday.

It may be a bit too soon based on what followed stateside but that's ok as I will build a position out again.

Good luck all 👍🏻

[tradermichael] 28/10/2023 07:14

I bought IN @ 1437.93 ...... ;0)

[abdullla] 27/10/2023 16:23

My fingers are not itching

[rikky72] 27/10/2023 15:34

Looks sectoral today..

[mj19] 27/10/2023 15:17

Madness this is

[lippy4] 27/10/2023 11:30

surely profit will increase because of inflation,but will it improve over that which would be real increase..

[tradermichael] 27/10/2023 10:04

4...

2023 to 2027 forecasts:

Turnover: 28,943 30,345 31,988 33,383 33,987

Net debt: (14,349) (11,397) (8,013) (4,187) (595)

Operating profit: 8,504 8,821 9,669 10,324 10,475

Earnings per share: 148.5 152.4 169.4 182.0 185.2

[tradermichael] 26/10/2023 08:24

3...

ViiV Healthcare receives approval from China's National Medical Products Administration (NMPA) for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine), the first and only complete long-acting HIV-1 injectable treatment

-- The marketing authorisation for rilpivirine long-acting injection was received on the 18 October 2023

-- The complete long-acting regimen enables people living with HIV in China, who are virologically suppressed to reduce the treatment dosing days from 365 to 12 or 6 per year after initiation.

-- With an estimated 1.045 million people living with HIV in China, expanding treatment options is critical to reduce the scale of the epidemic in the country.

[tradermichael] 25/10/2023 08:08

2...

In a strategic move to enhance its oncology portfolio, GSK plc has obtained an exclusive license to develop and commercialize HS-20089, a B7-H4 targeted antibody-drug conjugate (ADC) with topoisomerase inhibitor (TOPOi) payload technology. The drug, currently undergoing phase I trials in China, is designed to target gynaecologic cancers, specifically ovarian and endometrial cancer.

The agreement was facilitated by Senior VP Hesham Abdullah from GSK and Eliza Sun from Hansoh Pharma. As part of the deal, GSK will initiate phase I trials outside China in 2024 and make an upfront payment of $85 million to Hansoh. The agreement also includes the potential for success-based milestones up to $1.485 billion.

The license grants GSK global rights to develop and commercialize HS-20089, excluding mainland China, Hong Kong, Macau, and Taiwan. This acquisition is part of a growing trend of ADC deals in the pharmaceutical industry.

[tradermichael] 25/10/2023 08:06

1...

Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

The vaccine, which is currently approved in the States for the prevention of RSV-lower respiratory tract disease (LRTD) in adults aged 60 and above, was trialled on adults aged 50 to 59.

Arexvy, which has already been approved in Europe, Japan and several other countries, "elicited an immune response [...] that was non-inferior to that observed in adults aged 60 and above, meeting the trial's primary co-endpoint", GSK said in a statement on Wednesday.

[panache1] 24/10/2023 14:26

Not me ! Enough for now !

[abdullla] 24/10/2023 08:25

Anyone with itching fingers today ?

[rongetsrich] 21/10/2023 21:08

What a stupid thing to say, Abby.

[abdullla] 20/10/2023 14:49

Good for you but they were a lot cheaper earlier on.

[panache1] 20/10/2023 14:36

In ! 14.651

[panache1] 20/10/2023 14:34

I'm itching !

[abdullla] 19/10/2023 16:55

What's up,nobody IN today?

[rikky72] 19/10/2023 13:23

Whether one agrees or not, it's certainly an interesting debate. One thing that is clear to me is that on any given day separate, unconnected institutions have very different reasons for buying or selling and these decisions are more often not connected to the news on the day, if there is any, than people think.